TET2 truncating mutations predict a worse outcome in blastic plasmacytoid dendritic cell neoplasm

Blood Adv. 2023 May 23;7(10):2000-2003. doi: 10.1182/bloodadvances.2022007879.

Authors

Affiliations

¹ Department of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, TX.
² Department of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, TX.
³ Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX.
⁴ Department of Stem Cell Transplantation, University of Texas MD Anderson Cancer Center, Houston, TX.

No abstract available

Publication types

Research Support, U.S. Gov't, Non-P.H.S.
Research Support, Non-U.S. Gov't
Letter
Research Support, N.I.H., Extramural

MeSH terms

Acute Disease
DNA-Binding Proteins / genetics
Dendritic Cells
Dioxygenases* / genetics
Humans
Mutation
Myeloproliferative Disorders* / diagnosis
Myeloproliferative Disorders* / genetics
Neoplasms*

Substances

TET2 protein, human
DNA-Binding Proteins
Dioxygenases